Skip to content
Riskpilot
← Tilbage til søgning
Log ind
Få fuld adgang
POSEIDON PHARMACEUTICALS A/S
A/S
Dissolved
CVR 26133130
Strandvejen 60, 2900
Hellerup
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
·
NACE 721900
Est. 2001 · 24 years old
— employees
Overvåg
Share
Denmark
/
Companies
/
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
/
POSEIDON PHARMACEUTICALS A/S
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
0M
0M
1M
1M
1M
0M
2012
0M
2013
0M
2014
0M
2015
EBITDA
DKK millions
0M
-0M
-1M
-1M
-1M
0M
2012
0M
0%
2013
0M
0%
2014
0M
0%
2015
Income statement
DKK thousands
Item
2012
2013
2014
2015
Gross profit
—
—
—
—
Staff expenses
-0
-0
-0
-0
EBITDA
-17
-19
-17
-17
Depreciation & amort.
-0
-0
-0
-0
EBIT
-17
-19
-17
-17
Net financials
211
159
159
160
Profit before tax
194
140
142
143
Tax
-0
-0
-0
-0
Net profit
194
140
142
143
Balance sheet
DKK thousands
Item
2012
2013
2014
2015
Total assets
63.555
63.695
63.837
63.980
Equity
63.540
63.680
63.822
63.965
Long-term debt
0
0
0
0
Short-term debt
15
15
15
15
Total debt
15
15
15
15
Financial ratios
5-year trend
EBITDA-margin (af bruttofortjeneste)
-1700000.0%
This company
2012
2015
Soliditetsgrad
100.0%
This company
38.2%
Market median
+162% vs market
2012
2015
Egenkapitalforrentning
0.2%
This company
18.4%
Market median
-99% vs market
2012
2015
Nettoresultatgrad (af bruttofortjeneste)
14300000.0%
This company
2012
2015
Aktivomsætning (af bruttofortjeneste)
0.00×
This company
2012
2015
Gæld/egenkapital
0.00×
This company
0.62×
Market median
+100% vs market
2012
2015
Annual reports & filings
Annual report 2015
Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
View
PDF
Annual report 2014
Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
View
PDF
Annual report 2013
Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
View
PDF
Annual report 2012
Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
View
PDF
More on POSEIDON PHARMACEUTICALS A/S
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
